|1.||Gurbel, Paul A: 1 article (10/2002)|
|2.||Gibbons, Raymond J: 1 article (10/2002)|
|3.||Sheehan, Florence: 1 article (10/2002)|
|4.||HALT-MI Investigators: 1 article (10/2002)|
|5.||Chronos, Nicolas A F: 1 article (10/2002)|
|6.||Faxon, David P: 1 article (10/2002)|
|7.||Becker, Kyra J: 1 article (01/2002)|
|8.||Kopecky, S L: 1 article (09/2001)|
|9.||Breisblatt, W M: 1 article (09/2001)|
|10.||Gibbons, R J: 1 article (09/2001)|
|1.||Chronic Progressive Multiple Sclerosis
10/02/2002 - "The purpose of this study was to determine whether Hu23F2G (LeukoArrest), an antibody to the CD11/CD18 integrin receptors, would reduce infarct size in patients undergoing primary angioplasty for an acute myocardial infarction. "
10/02/2002 - "Patients within 6 h of onset of chest pain with ST-segment elevation were randomized to receive either 0.3 mg/kg or 1.0 mg/kg of Hu23F2G or placebo just before angioplasty of occluded arteries (Thrombolysis in Myocardial Infarction TIMI flow grade 0 or 1). "
|4.||Urinary Tract Infections (Urinary Tract Infection)
|5.||Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders)
|1.||Angioplasty (Angioplasty, Transluminal)